通过天然化合物增强粉样β抑制和分解:利用光谱,显微镜和细胞生物学进行的一项研究
Ranit Pariary1, Gourav Shome2, Tista Dutta1
1Department of Chemical Sciences, Bose Institute, Unified Academic Campus, Salt Lake, EN 80, Kolkata 700 091, India.
Biophysical chemistry
|July 19, 2024
概括
传统的印度医学Lasunadya Ghrita (LG) 显示出对阿尔茨海默病 (AD) 的治疗潜力. 它的水提取物 (LGWE) 抑制了粉样β (Aβ) 聚合,并保护神经元细胞免受Aβ毒性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 粉样蛋白和是神经退行性疾病的核心,如阿尔茨海默氏症 (AD).
- 虽然合成化合物表现有前途,但抑制氨基粉症的天然化合物尚未得到充分探索.
- 传统印度医学Lasunadya Ghrita (LG) 用于肠道和心理健康问题.
研究的目的:
- 调查用于阿尔茨海默氏病 (AD) 的重新设计的传统印度医学Lasunadya Ghrita (LG) 的潜力.
- 分析LG提取物对粉样β (Aβ) 聚合的抑制作用.
- 阐明LG对Aβ毒性的神经保护作用的机制性见解.
主要方法:
- 提取和表征各种LG组件.
- 生物物理研究 (例如,NMR) 来评估Aβ聚合抑制和结合部位.
- 使用神经元SH-SY5Y细胞进行体外研究来评估Aβ毒性.
- 在小鼠模型中进行体内毒性评估.
主要成果:
- 在LG (LGWE) 的水提取物有效抑制Aβ40/Aβ42聚合和除.
- 核磁共振研究显示,LGWE与Aβ40/Aβ42结合,调节聚合并减少细胞膜损伤.
- 在SH-SY5Y细胞中,LGWE通过减少氧化应激,膜泄漏,细胞亡和不平衡来证明神经保护.
- 在神经元细胞或小鼠模型中,LGWE没有表现出毒性.
结论:
- 重新利用的Lasunadya Ghrita水提取物 (LGWE) 在改善Aβ诱导的神经毒性和聚合方面显示出显著的潜力.
- 对于阿尔茨海默病的干预,LGWE提供了一种有前途的天然化合物方法.
- 对LGWE对抗Aβ诱导的神经炎症的机制进行进一步研究是有必要的.
更多相关视频
06:27Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
Published on: November 30, 2018
9.2K
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.2K
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K